REVENUE (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Net Revenue

The following table reflects summary revenue, net for the years ended December 31, 2023 and 2022 (in thousands):

	Year ended December 31,
	2023		2022
Product sales, net:
ROLVEDON	$	18,175	$	—
INDOCIN products	87,217		100,338
Sympazan	9,938		1,768
Otrexup	12,026		11,148
SPRIX	9,150		9,110
CAMBIA	8,070		24,720
Zipsor	3,460		3,364
Other products	1,415		4,673
Total product sales, net	149,451		155,121
Royalties and milestone revenue	2,433		2,403
Other revenue	185		(1,290)
Total revenues	$	152,069	$	156,234